Five months into Utah's Doctronic pilot — the first US program authorizing AI to recommend prescription renewals — the state just released outcome data. The AI's renewal recommendations are statistically indistinguishable from a second physician's. And when the AI defers to a human, it defers more often than a human would.

One year after analyzing FDA’s AI medical device approvals, a new dataset confirms: growth continues, but acceleration is absent. While more young companies are joining the field, older firms like GE still dominate approvals—classic sustaining innovation. And Big Tech? Still barely on the board.

Smartphone apps that can diagnose pneumonia? FDA-approved machines that can diagnose conditions without a doctor? Robot psychotherapy? It’s not coming, it’s here now.